Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Biodel has completed dosing in Phase II trial of investigational ultra-rapid-acting injectable mealtime insulin therapy BIOD-123 in patients with type 1 diabetes.
The open label, parallel group study had randomized 132 type 1 diabetes patients with either BIOD-123 or Humalog to use as their mealtime insulin during a treatment period of 18 weeks.
http://clinicaltrials.pharmaceutica...ing-in-phase-ii-trial-of-diabetes-drug-120713
The open label, parallel group study had randomized 132 type 1 diabetes patients with either BIOD-123 or Humalog to use as their mealtime insulin during a treatment period of 18 weeks.
http://clinicaltrials.pharmaceutica...ing-in-phase-ii-trial-of-diabetes-drug-120713